Biological product filing citing a New England Journal of Medicine paper — Sana Biotechnology, 2025-08-11
Sana BiotechnologySana BiotechnologyNASDAQ SANA
Filings SEC · Quote Yahoo cited a paper published in the New England Journal of Medicine as the basis for its claims in a regulatory filing with the U.S. Securities and Exchange CommissionU.S. Securities and Exchange Commission
Regulator · Website. The company read the way it wrote the paper and the actual scope of the paper in sequence. It described where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.
The disclosure wrote the paper like this in the press release
When a U.S.-listed company has something to inform its shareholders, the form it files with the Securities and Exchange Commission is called 8-K. The item numbers in the document filed by Sana Biotechnology on 2025-08-11 were 2.02 Earnings Release · 9.01 Financial Statements and Exhibits. The company cited a paper published in New England Journal of Medicine in the press release attached to it. If the sentence citing the paper is translated verbatim, it reads as follows.
“We are pleased with the progress with the type 1 diabetes program, including recent FDA feedback on our HIP-edited GMP master cell bank and non-clinical testing plan for SC451, positive UP421 6-month clinical results presented at an invited talk at the American Diabetes Association Annual Meeting and World Transplant Congress 2025, and UP421 3-month clinical results published in the New England Journal of Medicine ,” said Steve Harr, Sana’s President and Chief Executive Officer.
What the reader should first check is where the company placed the paper in the press release. Next, the reader should determine whether the paper supports the entire company claim or only a part of it. To answer the latter question, one must read the full paper. This article, which has only read the abstract, cannot provide an answer to that.
The scope of the paper mentioned in the abstract is limited to this.
The paper title is Survival of Transplanted Allogeneic Beta Cells with No Immunosuppression and it was published in New England Journal of Medicine on 2025-08-04. The authors' affiliations are Uppsala University · Sana Biotechnology (United States) · Oslo University Hospital · Karolinska Institutet. The summary at the beginning of the paper is called abstract. This article has read only up to this point. The paragraph was written by a person after filtering out a draft written by a machine by comparing numbers, so it is of a different grade than a full reading of the paper.
A case report of a male with long-term type 1 diabetes who received donor pancreatic islet cells implanted into the arm muscle, with the genes modified to avoid immune rejection. The cells were modified using gene scissors and lentivirus to prevent them from being attacked by immune cells. The patient did not use any immunosuppressive drugs, and no immune response to the modified cells was observed 12 weeks after the transplant. Since this is the result from one person over 12 weeks, whether the effect lasts long-term or applies to multiple people is beyond this report.
What the abstract does not answer remains in the full paper and its appendices. This article, which has not gone beyond the abstract, leaves the blanks as they are. Readers should determine themselves which sentence in the abstract corresponds to the excerpt cited by the company, by comparing the two citations above.
One month later, the stock price was within the middle half of the sample.
The remaining return after subtracting the portion that moves with the overall market is called excess return. The date is written as trading day, counting only the days the stock market is open. In calendar terms, 20 trading days are approximately one month. The excess return for the day of the regulatory filing and the following month are listed in the table below.
| Period | Excess return relative to the market | Meaning |
|---|---|---|
| Five trading days before the filing | −22.0% | The extent of movement before the filing |
| On the day of the filing | −2.5% | On the filing day or the first trading day thereafter |
| Accumulated over +1 to +5 trading days | +10.0% | One week |
| Cumulative +1~+20 trading days | −1.4% | One month |
A bundle of past cases of the same type is called a sample. The position counted from the bottom is expressed as a percentile. The one-month excess return of -1.4% in this case is within the bottom 62% of the 142 samples, placing it in the lower half.
| Sample scale (20 trading days) | Tenth from the bottom | Fourth from the bottom | median | top 25% | top 10% | This case |
|---|---|---|---|---|---|---|
| Excess return | −31.9% | −20.1% | −7.4% | +5.5% | +19.5% | −1.4% |
Half of the sample falls between the two marks in the middle of the table. One checks from the table whether this case is inside or outside. The sample collects cases where U.S. listed companies wrote papers in 8-K over the past ten years. The company itself is excluded from the sample. The numbers written here are past facts, not rules to apply to the next case.
After the regulatory filing, the company issued such documents
After the filing date, the company issued three 8-K filings, listed only by item numbers. In 8-K filings without titles, the item number indicates the type of content. One can determine whether it was an earnings announcement or a contract based on that number. What exactly occurred is read in the original text of each link.
- 2025-08-29 8-K Item 5.02 — Changes in Directors and Executive Officers
- 2025-09-05 8-K Item 5.02, 8.01 — Officer and Director Changes · Other Events
- 2025-11-06 8-K Item 2.02, 9.01 — Earnings Announcement · Financial Statements · Attached Documents
What this article does not answer
This article, which reads only the abstract, cannot answer what the paper reviewed, how it was done, or how far it went. How many times the paper cited by the company was cited afterward can be checked again using the OpenAlexOpenAlex
Data source · Website citation count. What will be seen next is whether the company's next 8-K again cites the same paper.
Glossary
- 8-K
- A voluntary report submitted to the Securities and Exchange Commission when a U.S. listed company has something to inform shareholders. Types are indicated by item numbers such as earnings, contracts, and executive changes. All events in this article come from this document.
- Excess return
- The remainder after subtracting the overall market return from the stock return. It is used to see the movement of this company alone by removing the portion where the market rises and falls together.
- Trading day
- A date counting only days when the stock market is open. Since weekends and holidays are excluded, 20 trading days correspond to roughly one calendar month.
- Sample and percentile
- A bundle of past cases of the same type is a sample, and the position from the bottom is expressed as a percentile. A percentile of 10 means that nine out of ten cases performed better than this case.
- Abstract
- An abstract is placed at the beginning of a paper. The author writes in a few sentences what was done, how it was done, and what results were obtained. Without reading the full text, one cannot know the details or limitations of the methods.